1Pascrual E,Comez-Amau J,Pensado A,et al.Incidence and risk factors of early acute renal failure in liver transplant patients[J].Transpl,1993,25:1937-1946.
4Kahan BD,Dunn J,Fitts C,et.al. Reduced inter- and intrasubject variability in cyclosporine pharmacokinetics in renal transplant recipients treated with a microemulsion formulation in conjunction with fasting, low-fat meals, or high-fat meals.Transplantati
5Levy GA.Neoral use in the liver transplant recipient. Transplant Proc, 2000, 32(Suppl 3A):2S-9S.
6Pietro A, Maurizio B, Annagiulia G, et al. Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant hepatitis B virus infection awaiting liver transplantation. Transplantation 2002, 74:1119-1124.
7Angus PW, McCaughan GU, Gane EJ, et al. Combination low dose hepatitis B immune globulin (HBIG) and lamivudine therapy provides effective prophylaxis against post transplant hepatitis B. J Gastroenterol Hepatol, 1999,14 (suppl):A133.
8Core Working Party for Asia-Pacific consensus on hepatitis B and C. Consensus statements on prevention and management of hepatitis B and hepatitis C in the Asia-Pacific region. J Gastroenterol Hepatol, 2000,15:825-841.
9McCaughan GW. Indications for liver transplantation for chronic viral hepatitis and therapies for controlling hepatitis B virus infection before and after transplantation. J Gastroenterol Hepatol. 2000, 15(suppl):E172-174.
10Techerverkow JI, Tector AJ, Barkun JS, et al. Recurrence-free long-term survival after liver transplantation for hepatitis B using interferon-alpha pretransplant and hepatitis B immune globulin posttransplant. Ann Surg, 1997, 226:356-368.
